Featured

Status

Health Topics

Any Category
Diseases
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Genetic Diseases, Inborn
Clear Filters

Search Clinical Trials

16 Results
Not Yet Recruiting
Zinc Supplementation in Sickle Cell Disease
The investigators propose a two-arm, double-blinded, Phase II study comparing the effects of two different daily doses of zinc (25 and 40 mg/day) in 34 patients with SCD-SS aged 15-35 …
Baylor Role: Collaborator
Recruiting
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a …
Baylor Role: Collaborator
Completed
Fetal Hemoglobin Induction Treatment Metformin
This is a dose escalation, pilot study for subjects with sickle cell anemia (SCA) disease to determine if metformin has a beneficial effect on the treatment and quality of life …
Baylor Role: Lead Sponsor
Recruiting
Investigation of the Genetics of Hematologic Diseases
Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies …
Baylor Role: Collaborator
Terminated
Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
Patients will be recruited from the patient population followed at the Texas Children's Cancer and Hematology Centers (TCC/HC)/Baylor College of Medicine (BCM) and the University of Texas Houston Hematology Center. …
Baylor Role: Lead Sponsor
Terminated
Treatment of Hemoglobin SC Disease With Hydroxyurea
To be eligible to participate in this study, patients must have HbSC disease, have experienced a sickle cell disease related complication, or have a score of 80 or lower on …
Baylor Role: Lead Sponsor
Recruiting
Sickle Cell Clinical Research and Intervention Program
The St. Jude Pediatric SCD Program has developed a comprehensive plan of care that spans the ages of 0 to 25, and provides the structure for screening and monitoring disease …
Baylor Role: Collaborator
Completed
Novel Dose Escalation to Predict Treatment With Hydroxyurea
To be eligible to participate in this study, patients must have decided that they want to begin hydroxyurea therapy. Patients choosing to participate in this study will be assigned randomly …
Baylor Role: Lead Sponsor
Completed
A Phase II Trial of Regadenoson in Sickle Cell Anemia
If you are willing to participate in this research study you will be asked to undergo some screening tests and procedures to confirm your eligibility. Many of these tests and …
Baylor Role: Collaborator
Terminated
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea
Despite the clear results of the STOP and the follow-up STOP II trials, the use of chronic erythrocyte transfusions for primary stroke prevention in children with Sickle Cell Anemia (SCA) …
Baylor Role: Collaborator